239 related articles for article (PubMed ID: 22024515)
1. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
2. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
3. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
4. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
Sun M; Li C; Xu W; Liao G; Li R; Zhou J; Li Y; Cai W; Yan D; Che Y; Ying Z; Wang J; Yang H; Ma Y; Ma L; Ji G; Shi L; Jiang S; Li Q
Clin Infect Dis; 2017 May; 64(10):1317-1325. PubMed ID: 28419204
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
6. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
7. Detection of mutants in polio vaccine viruses using pooled antipoliovirus monoclonal antibodies.
Horie H; Sato-Miyazawa M; Ota Y; Wakabayashi K; Doi T; Yoshizawa K; Doi Y; Hashizume S
Biologicals; 1999 Sep; 27(3):217-26. PubMed ID: 10652177
[TBL] [Abstract][Full Text] [Related]
8. Mapping of type 1 poliovirus neutralization epitopes.
Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of poliovirus antibody titers in orally vaccinated semi-captive chimpanzees in Uganda.
Mugisha L; Pauli G; Opuda-Asibo J; Joseph OO; Leendertz FH; Diedrich S
J Med Primatol; 2010 Apr; 39(2):123-8. PubMed ID: 20102460
[TBL] [Abstract][Full Text] [Related]
10. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.
Nagata N; Iwasaki T; Ami Y; Sato Y; Hatano I; Harashima A; Suzaki Y; Yoshii T; Hashikawa T; Sata T; Horiuchi Y; Koike S; Kurata T; Nomoto A
Virology; 2004 Mar; 321(1):87-100. PubMed ID: 15033568
[TBL] [Abstract][Full Text] [Related]
11. Antibody response of children immunized with poliovaccines: an evaluation using two strains of poliovirus type 1.
Deshpande JM; Dave KH
Indian J Med Res; 1992 Sep; 95():216-20. PubMed ID: 1335965
[TBL] [Abstract][Full Text] [Related]
12. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
13. Isolation of an intertypic poliovirus capsid recombinant from a child with vaccine-associated paralytic poliomyelitis.
Martín J; Samoilovich E; Dunn G; Lackenby A; Feldman E; Heath A; Svirchevskaya E; Cooper G; Yermalovich M; Minor PD
J Virol; 2002 Nov; 76(21):10921-8. PubMed ID: 12368335
[TBL] [Abstract][Full Text] [Related]
14. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
15. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
18. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
19. Correlation between vaccine coverage against polio and circulation and genetic evolution of the poliovirus strains isolated in Romania in the framework of the global polio eradication strategy.
Băicuş A; Persu A; Popescu M; Penciu A; Stavri S; Soare A; Grecu N; Szmal C; Oprişan G
Roum Arch Microbiol Immunol; 2009; 68(3):145-50. PubMed ID: 20361534
[TBL] [Abstract][Full Text] [Related]
20. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
